CASTLE ROCK, CO – April 16, 2020 – Today Infinity Laboratories (infinitylaboratories.com) added a validated method for Hydroxychloroquine to its expanding catalog of capabilities and is now receiving final product samples for potency testing.

Hydroxychloroquine (HCQ) is an antimalarial drug effective in the treatment of various autoimmune rheumatic diseases including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) that is under investigation in clinical trials for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 infection, and treatment of patients with mild, moderate, and severe COVID-19.
(https://ncbi.nlm.nih.gov/pmc/articles/PMC5137978/ and https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html)

Method development is the process of proving that an analytical method is acceptable for use to measure the concentration of an API in a specific compounded dosage form which allow simplified procedures to be employed to verify that an analysis procedure, accurately and consistently will deliver a reliable measurement of an active ingredient in a compounded preparation. The analytical method validation is essential for method development and extensive testing is performed to display specificity, linearity, accuracy, precision, range, detection limit, quantization limit, and robustness. In summary, analytical method development and validation allows us to confirm that an accurate and reliable potency measurement of a pharmaceutical preparation can be performed.

For more information contact:

Hank Nowak
SVP, Commercial Operations
Infinity Laboratories
phone: 843-475-0155
e-mail: hnowak@infinitylaboratories.com